Pyxis Oncology FY EPS $(1.85) Beats $(1.95) Estimate; Cash And Cash Equivalents Of $120.8M And Gross Procced Of $10.8M and $50M Via ATM Offering And Private Placement Is Expected To Provide Cash Runway Into 2H 2026
Author: Benzinga Newsdesk | March 21, 2024 07:41am
Pyxis Oncology (NASDAQ:
PYXS) reported quarterly losses of $(1.85) per share which beat the analyst consensus estimate of $(1.95) by 5.13 percent. This is a 49.32 percent increase over losses of $(3.65) per share from the same period last year.
Posted In: PYXS